Skye confirms phase 2 data on nimacimab for obesity expected later this year

Stock Information for Skye Bioscience Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Skye Bioscience Inc.

Skye Bioscience, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before January 16, 2026 to Discuss Your Rights - SKYE
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience
SKYE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Skye Bioscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
ATTENTION NASDAQ: SKYE INVESTORS: Contact Berger Montague About a Skye Bioscience, Inc. Class Action Lawsuit
The Gross Law Firm Reminds Skye Bioscience, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 16, 2026 - SKYE
SKYE LAWSUIT ALERT: The Gross Law Firm Notifies Skye Bioscience, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience
SKYE INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.